

Author Index to Volume 16

- Adelman, M.H., 255
Ali, R.V., 255
Allen, S.D., 191
Amaral, J.L.G., 9
Archer, G.L., 223
Arens, M., 165
Ashley, M.A., 25
Atkins, L.M., 25
Auger, P., 223
- Bale, M.J., 1, 53, 119
Ballow, C.H., 255
Balows, A., 149
Beaman, B.L., 291
Bohnert, V.A., 325
Bonai, J., 137
Bratcher, J.L., 83
Brown, B.A., 215
Buck, R.L., 17
Burnham, J.C., 277
Buschelman, B.J., 53, 119
Butler, W.R., 321
- Cabezudo, I., 53
Chacko, T.M., 331
Chapin-Robertson, K., 173
Chiew, Y.-F., 145
Chow, C., 61
Chow, J.W., 343
Clabots, C.R., 303
Cobo, J., 79
Comeau, S., 93
Cost, K., 75
Craig, W.A., 231
Cumbo, T.J., 255
Czinn, S.J., 317
- Dalton, H.P., 43
Dalton, M.T., 93
Davis, T.E., 99
Densel, M., 53
Doern, G.V., 141, 223, 227
Drehobl, M., 123
Dunagan, W.C., 265
- Eliopoulos, G.M., 111
Eng, R.H.K., 185
Erwin, M.E., 191
- Fan-Havard, P., 185
Fasching, C.E., 303
Ferraro, M.J., 223, 275
Flint, K.K., 205
Forward, K.R., 93
Fritz, A.L., 255
Fuchs, P.C., 191, 223
Fuller, D.D., 99
- Galletta, V.A., 255
Gerding, D.N., 303
Gerlach, E.H., 111, 191
Gilmore, D.S., 25
- Granato, P.A., 237
Griffith, B.P., 331
Griffith, D.E., 215
Guerrero, A., 79
Gutfeld, M.B., 255
- Hampton, C.M., 83
Hartstein, A.I., 35
Henery, M.L., 325
Hoban, D.J., 111
Hollis, R., 1, 9
Hoover, W.W., 111
Howe, T., 53
Hsieh, M.H., 343
- Jadusingh, I.H., 67
Jesudason, M.V., 73
John, J.F., 25
John, T.J., 73
Johnson, F.B., 61
Johnston, S.L.G., 87
Jones, R.N., 9, 111, 119, 191, 205
Jorgensen, J.H., 151, 223, 245
- Kabani, A.M., 67
Kilburn, J.O., 321
Kjellstrom, J.A., 291
- Lagging, L.M., 317
Lambert, K., 93
Laszlo, A., 321
Lee, B.C., 67
Leme, I.L., 9
Linton, H.J., 53
Low, D.E., 223
Loza, E., 79
Luker, G., 61
- Marshall, G.S., 75
Marx, C.E., 313
Mastin, S.H., 17
Medoff, G., 265
Meier, F.A., 43
Midkiff, B.R., 317
Miller, J.M., 153
Mirelis, B., 137
Miro, E., 137
Mirrett, S., 31
Moellering, R.C., Jr., 223
Montgomerie, J.Z., 25
Morris, A., 313
Morthland, V.H., 35
Mueggler, P.A., 17
Murray, P.R., 83, 151, 191, 223
- Navarro, F., 137
Navas, E., 79
Niles, A.C., 83
- Ogalla, C.A., 137
Ogbara, T., 185
Olsen, M.A., 105, 325
- Omran, Y., 131
- Paladino, J.A., 255
Persing, D.H., 159
Peterson, L.R., 303
Petzel, R.A., 303
Pfaller, M.A., 1, 9, 53, 111
Pien, F., 123
Pignatari, A., 9
Prasad, E.S., 135
Prats, G., 137
- Rabalais, G.P., 75
Rainnie, B., 93
Rashad, A.L., 35
Reimer, L.G., 31
Reller, L.B., 31, 223, 313
Rodrigues, J.N., 9
Rosenblatt, J.E., 337
Rourke, J.W., 35
- Sambol, A.R., 105, 325
Sanchez, M.L., 205
Sanford, M., 1
Santhosh, M., 73
Satishchandran, V., 89
Sayahtheri-Altaie, S., 43
Schentag, J.J., 255
Schneider, S.K., 337
Sharp, S.E., 251
Shuck, K.M., 105, 325
Siddiqi, S.H., 321
Sloan, L.M., 337
Smith, S.M., 185
Sonstein, S.A., 277
Sridharan, G., 73
Stevens, D.L., 123
Stratton, C.W., 223
Sykes, R., 35
- Tosaka, M., 145
Truant, A.L., 89
- Vautour, R., 141
Vitug, M., 53
- Waldeyer, S., 75
Wallace, R.J., Jr., 215
Weinstein, M.P., 31
Wenman, W.M., 135
Wennersten, C.B., 223
Westblom, T.U., 317
Wey, S., 9
Williams, J.D., 255
Wilson, M.L., 31, 313
Wood, C.A., 131
- Yamane, N., 145
Yao, J.D.C., 67
Youmans, G.R., 99
Yu, C.M., 343
Yu, V.L., 343

Subject Index to Volume 16

- Abbott TestPack RSV, for diagnosis of respiratory syncytial virus infections, 105-109
- Abdominal abscess, invasive candidiasis associated with, 57
- Acetylsalicylic acid, in teicoplanin fluorescence polarization immunoassay, 21
- Acinetobacter calcoaceticus*
ampicillin-sulbactam against, 199
cefazolin against, 199
cefonicid against, 199
cefoperazone against, 199
cefotaxime against, 199
cefotetan against, 199
ceftazidime against, 199
ceftizoxime against, 199
ceftriaxone against, 199
cefuroxime against, 199
imipenem against, 199
ticarcillin against, 199
- AccuProbe assay
in confirmatory testing for gonococcus, 178-180
in detection of oxacillin resistance in *Staphylococcus aureus*, 99-104
- Acetylsalicylic acid, in teicoplanin fluorescence polarization immunoassay, 21
- Acinetobacter* spp., rifaximin against, 113
- Acquired immunodeficiency syndrome (AIDS), unusual mycobacteria in, 321-323
- Actinomyces* spp., in murine model for recognition of nocardial infections, 291-301
- Active intervention, problems of, 242
- Acute abdomen, invasive candidiasis associated with, 57
- Acyclovir, against herpes virus, 114
- Administrative methods, for controlling antimicrobial usage, 266
- Aerococcus* spp., identification of, 121
- AIDS. See Acquired immunodeficiency syndrome
- Albumin, abnormal levels of, in teicoplanin recovery, 17-24
- Amikacin
against Gram-negative bacilli, 248
against *Mycobacterium avium-intracellulare* complex, 114, 351
against *Mycobacterium chelonae-fortuitum*, 114, 351
qualitative susceptibility tests and, 235
quantitative MIC tests and, 235
against *Staphylococcus aureus*, 12
in teicoplanin fluorescence polarization immunoassay, 21
- Aminoglycosides
against enterococci, 119-122, 145-148
qualitative susceptibility tests and, 233, 235
quantitative MIC tests and, 233, 235
- Amoxicillin-clavulanic acid
against Gram-negative bacilli, 248
against *Haemophilus influenzae*, 249
- Amphotericin B, against invasive candidiasis, 53-60
- Ampicillin
against *Bacteroides bivius-disiens*, 116
against *Enterococcus* spp., 248
against *Gardnerella vaginalis*, 116
against *Gemella morbillorum*, 132
against Gram-negative bacilli, 248
against *Haemophilus influenzae*, 249
against *Klebsiella pneumoniae*, 25-29
against *Lactobacillus* spp., 24
against *Mobiluncus* spp., 116
in teicoplanin fluorescence polarization immunoassay, 21
- Ampicillin-sulbactam
against *Acinetobacter calcoaceticus*, 199
against *Citrobacter freundii*, 196
against coagulase-negative streptococci, 193
endotoxin release and, 185-189
against *Enterobacter aerogenes*, 196
against *Enterobacter cloacae*, 196
against *Enterococcus* spp., 194
against *Escherichia coli*, 197
against Gram-negative bacilli, 248
against *Haemophilus influenzae*, 201, 249
against *Haemophilus parainfluenzae*, 201
against *Klebsiella oxytoca*, 197
against *Klebsiella pneumoniae*, 197
against *Moraxella catarrhalis*, 201
against *Morganella morganii*, 197
against *Neisseria gonorrhoeae*, 202
against *Neisseria* spp., 202
against *Prevotella bivia-disiens*, 202
against *Proteus mirabilis*, 197
against *Proteus vulgaris*, 198
against *Providencia rettgeri*, 198
against *Providencia stuartii*, 198
against *Pseudomonas aeruginosa*, 199
against *Salmonella* spp., 198
against *Serratia marcescens*, 199
against *Shigella* spp., 199
against *Staphylococcus aureus*, 192-193
against *Streptococcus agalactiae*, 193
against *Streptococcus pneumoniae*, 194
against *Streptococcus pyogenes*, 193
against *Streptococcus*, viridans group, 194
- Antibiograms
in hospital epidemiology, 153-157
predictive susceptibilities based on, 253
- Antimicrobials
changes in usage of, 255-264
formulary controls of, 265-274
selection of for routine testing in clinical microbiology laboratory, 245-249
- API 20S system, for enterococcal species identification, 119-122
- API Uriscreeen, for bacteriuria, 93-97
- Arthritis, septic, *Gemella morbillorum* in, 131-134
- Ascaris lumbricoides*
conventional microscopic examination for, 339
ELISA for, 339
- Azithromycin, against staphylococci, 205-213
- Aztreonam
endotoxin release and, 185-189
against *Haemophilus ducreyi*, 116
- Bacillus cereus*, rifaximin against, 111-118
- Bacitracin, against *Staphylococcus aureus*, 9-16
- BacT/Alert blood culture system, incubation times in, 31-34
- BACTEC 6A bottles, in oxacillin susceptibility testing, 99-104
- BACTEC 660/370 nonradiometric blood culture system, incubation times in, 31-34
- BACTEC NR blood cultures, in isolation of *Brucella* spp., 79-81
- Bacteremia
BacT/Alert blood culture system in assessment of, 31-34
Gram-negative bacillary, aminoglycosides against, 235
- Bacterial vaginosis
Centers for Disease Control 1991 estimates of, 174
direct detection of, 181-183
rifaximin against, 111-118
- Bacteriuria, screening tests for, 93-97
- Bacteroides bivius-disiens*
ampicillin against, 116
clindamycin against, 116
metronidazole against, 116
rifaximin against, 111-118
- Bacteroides fragilis*
ampicillin-sulbactam against, 202
cefazolin against, 202
cefonicid against, 202
cefotetan against, 202
cefoxitin against, 202
ceftazidime against, 202
ceftriaxone against, 202
cefuroxime against, 202
imipenem against, 202
ticarcillin-clavulanate against, 202
- Barbital buffer extract, in *Salmonella* (A-E) polyvalent antiserum preparation, 73
- Barnes Hospital control program, for antimicrobial usage, 266-270
- Benzoic acid, in *Serratia marcescens* biotyping system, 2-3
- β -lactam antibiotics, in vitro activity of, 191-203
- Bile, *Serratia marcescens* in, 5
- Bilirubin, abnormal levels of, in teicoplanin recovery, 17-24
- Biotyping
in hospital epidemiology, 153-157
of *Klebsiella oxytoca*, 35-41
of *Klebsiella pneumoniae*, 35-41

- of *Serratia marcescens*, 1-7
- Bitter taste, in clarithromycin therapy, 215-221
- Bivalent stain, for herpes simplex virus detection, 87-88
- Blastocystis hominis*
conventional microscopic examination for, 339
ELISA for, 339
- Blood culture testing
of *Brucella* spp., 79-81
incubation times in, 31-34
for invasive candidiasis, 53-60
- Blood culture therapy, audit of, 241
- Bloodstream isolates
of *Serratia marcescens* in, 1-7
of *Staphylococcus aureus*, 9-16
- Body mass, in clarithromycin therapy, 215-221
- Borrelia burgdorferi*, species-specific, non-cross-reactive proteins of, 43-51
- Bowel obstruction, invasive candidiasis associated with, 57
- Brain-heart infusion agar plants, in assessment of aminoglycoside resistance, 145-148
- Bromthymol blue, aqueous, in *Serratia marcescens* biotyping system, 2
- Broth microdilution testing, of quinolone-resistant *Staphylococcus aureus* strains, 9-16
- Brucella* spp., detection of from blood cultures, 79-81
- C1008 cells, in rapid detection of herpes simplex virus, 61-66
- Caffeine, in teicoplanin fluorescence polarization immunoassay, 21
- Campylobacter jejuni*-*coli*, ciprofloxacin against, 137-139
- Candida albicans*
BaC/Alert blood culture system in assessment of, 33
biotyping of, 6
in invasive candidiasis, 57
- Candida krusei*, in invasive candidiasis, 57
- Candida lusitanae*, in invasive candidiasis, 57
- Candida parapsilosis*, in invasive candidiasis, 56
- Candida* spp.
in bacteriuria, 94
in invasive candidiasis, 57
rifaximin against, 111-118
- Candida tropicalis*, in invasive candidiasis, 57
- Candidiasis, invasive, amphotericin B against, 53-60
- Candiduria, enzyme immunoassay diagnosis of, 53-60
- DL-Carnitine, in *Serratia marcescens* biotyping system, 2-3
- Catalase, in bacteriuria, 93-97
- Catheter, *Serratia marcescens* in, 5
- Cefaclor
against *Haemophilus influenzae*, 249
against *Staphylococcus aureus*, 12, 126-127
against *Staphylococcus epidermidis*, 126-127
against *Staphylococcus* spp., 123-129
against *Staphylococcus warneri*, 126-127
- Cefazolin
against *Acinetobacter calcoaceticus*, 199
against *Bacteroides fragilis*, 202
against *Citrobacter diversus*, 196
against *Citrobacter freundii*, 196
against coagulase-negative streptococci, 193
against *Enterobacter aerogenes*, 196
against *Enterobacter cloacae*, 196
against *Enterococcus* spp., 194
against *Escherichia coli*, 196
against Gram-negative bacilli, 248
against *Haemophilus influenzae*, 200
against *Haemophilus parainfluenzae*, 201
against *Klebsiella oxytoca*, 197
against *Klebsiella pneumoniae*, 197
against *Moraxella catarrhalis*, 201
against *Morganella morganii*, 197
against *Neisseria gonorrhoeae*, 202
against *Neisseria* spp., 202
against *Prevotella bivia*-*disiens*, 202
against *Proteus mirabilis*, 197
against *Proteus vulgaris*, 198
against *Providencia rettgeri*, 198
against *Providencia stuartii*, 198
against *Pseudomonas aeruginosa*, 199
against *Salmonella* spp., 198
against *Serratia marcescens*, 199
against *Shigella* spp., 199
against *Staphylococcus aureus*, 192
against *Staphylococcus* spp., 248
against *Streptococcus agalactiae*, 193
against *Streptococcus pneumoniae*, 194
against *Streptococcus pyogenes*, 193
against *Streptococcus* spp., 248
against *Streptococcus*, viridans group, 193
in teicoplanin fluorescence polarization immunoassay, 21
- Cefdaloxine (RU29246), against *Staphylococcus aureus*, 12
- Cefdinir, against *Staphylococcus aureus*, 12
- Cefixime
against Gram-negative bacilli, 248
against *Haemophilus influenzae*, 249
against *Staphylococcus aureus*, 12
- Cefmenoxime
qualitative susceptibility tests and, 233-234
quantitative MIC tests and, 233-234
- Cefmetazole, against Gram-negative bacilli, 248
- Cefonicid
against *Acinetobacter calcoaceticus*, 199
against *Bacteroides fragilis*, 202
against *Citrobacter diversus*, 196
against *Citrobacter freundii*, 196
against coagulase-negative streptococci, 193
against *Enterobacter aerogenes*, 196
against *Enterobacter cloacae*, 196
against *Enterococcus* spp., 194
against *Escherichia coli*, 196
against *Haemophilus influenzae*, 200
against *Haemophilus parainfluenzae*, 201
against *Klebsiella oxytoca*, 197
against *Klebsiella pneumoniae*, 197
- against *Moraxella catarrhalis*, 201
against *Morganella morganii*, 197
against *Neisseria gonorrhoeae*, 202
against *Neisseria* spp., 202
against *Prevotella bivia*-*disiens*, 202
against *Proteus mirabilis*, 197
against *Proteus vulgaris*, 198
against *Providencia rettgeri*, 198
against *Providencia stuartii*, 198
against *Pseudomonas aeruginosa*, 199
against *Salmonella* spp., 198
against *Serratia marcescens*, 199
against *Shigella* spp., 199
against *Staphylococcus aureus*, 192
against *Streptococcus agalactiae*, 193
against *Streptococcus pneumoniae*, 194
against *Streptococcus pyogenes*, 193
against *Streptococcus*, viridans group, 193
- Cefoperazone
against *Acinetobacter calcoaceticus*, 199
against *Bacteroides fragilis*, 202
against *Citrobacter diversus*, 195
against *Citrobacter freundii*, 196
against coagulase-negative streptococci, 193
against *Enterobacter aerogenes*, 196
against *Enterobacter cloacae*, 196
against *Enterococcus* spp., 194
against *Escherichia coli*, 196, 277
against *Haemophilus influenzae*, 200
against *Haemophilus parainfluenzae*, 201
against *Klebsiella oxytoca*, 197
against *Klebsiella pneumoniae*, 197
against *Moraxella catarrhalis*, 201
against *Morganella morganii*, 197
against *Neisseria gonorrhoeae*, 202
against *Neisseria* spp., 202
against *Prevotella bivia*-*disiens*, 202
against *Proteus mirabilis*, 197
against *Proteus vulgaris*, 198
against *Providencia rettgeri*, 198
against *Providencia stuartii*, 198
against *Pseudomonas aeruginosa*, 199
against *Salmonella* spp., 198
against *Serratia marcescens*, 199
against *Shigella* spp., 199
against *Staphylococcus aureus*, 192-193
against *Streptococcus agalactiae*, 193
against *Streptococcus pneumoniae*, 194
against *Streptococcus pyogenes*, 193
against *Streptococcus*, viridans group, 194
- Cefotaxime
against *Acinetobacter calcoaceticus*, 199
against *Bacteroides fragilis*, 202
against *Citrobacter diversus*, 195
against *Citrobacter freundii*, 196
against coagulase-negative streptococci, 193
against *Enterobacter aerogenes*, 196
against *Enterobacter cloacae*, 196
against *Enterococcus* spp., 194
against *Escherichia coli*, 196, 277
against Gram-negative bacilli, 248
against *Haemophilus influenzae*, 200, 249
against *Haemophilus parainfluenzae*, 201
against *Klebsiella oxytoca*, 197
against *Klebsiella pneumoniae*, 197

- against *Moraxella catarrhalis*, 201
 against *Morganella morganii*, 197
 against *Neisseria gonorrhoeae*, 202
 against *Neisseria* spp., 202
 against *Prevotella bivia-disiens*, 202
 against *Proteus mirabilis*, 197
 against *Proteus vulgaris*, 198
 against *Providencia rettgeri*, 198
 against *Providencia stuartii*, 198
 against *Pseudomonas aeruginosa*, 199
 against *Salmonella* spp., 198
 against *Serratia marcescens*, 199
 against *Shigella* spp., 199
 against *Staphylococcus aureus*, 12, 192-193
 against *Streptococcus agalactiae*, 193
 against *Streptococcus pneumoniae*, 194
 against *Streptococcus pyogenes*, 193
 against *Streptococcus*, viridans group, 194
 in teicoplanin fluorescence polarization immunoassay, 21
- Cefotetan**
 against *Acinetobacter calcoaceticus*, 199
 against *Bacteroides fragilis*, 202
 against *Citrobacter diversus*, 195
 against *Citrobacter freundii*, 196
 against coagulase-negative streptococci, 193
 against *Enterobacter aerogenes*, 196
 against *Enterobacter cloacae*, 196
 against *Enterococcus* spp., 194
 against *Escherichia coli*, 196
 against Gram-negative bacilli, 248
 against *Haemophilus influenzae*, 200
 against *Haemophilus parainfluenzae*, 201
 against *Klebsiella oxytoca*, 197
 against *Klebsiella pneumoniae*, 197
 against *Moraxella catarrhalis*, 201
 against *Morganella morganii*, 197
 against *Neisseria gonorrhoeae*, 202
 against *Neisseria* spp., 202
 against *Prevotella bivia-disiens*, 202
 against *Proteus mirabilis*, 197
 against *Proteus vulgaris*, 198
 against *Providencia rettgeri*, 198
 against *Providencia stuartii*, 198
 against *Pseudomonas aeruginosa*, 199
 against *Salmonella* spp., 198
 against *Serratia marcescens*, 199
 against *Shigella* spp., 199
 against *Staphylococcus aureus*, 12, 192-193
 against *Streptococcus agalactiae*, 193
 against *Streptococcus pneumoniae*, 194
 against *Streptococcus pyogenes*, 193
 against *Streptococcus*, viridans group, 194
 in teicoplanin fluorescence polarization immunoassay, 21
- Cefotizoxime**
 against *Acinetobacter calcoaceticus*, 199
 against *Bacteroides fragilis*, 202
 against *Citrobacter diversus*, 195
 against *Citrobacter freundii*, 196
 against coagulase-negative streptococci, 193
 against *Enterobacter aerogenes*, 196
 against *Enterobacter cloacae*, 196
 against *Enterococcus* spp., 194
 against *Escherichia coli*, 196
 against Gram-negative bacilli, 248
 against *Haemophilus influenzae*, 200
 against *Haemophilus parainfluenzae*, 201
 against *Klebsiella oxytoca*, 197
 against *Klebsiella pneumoniae*, 197
 against *Moraxella catarrhalis*, 201
 against *Morganella morganii*, 197
 against *Neisseria gonorrhoeae*, 202
 against *Neisseria* spp., 202
 against *Prevotella bivia-disiens*, 202
 against *Proteus mirabilis*, 197
 against *Proteus vulgaris*, 198
 against *Providencia rettgeri*, 198
 against *Providencia stuartii*, 198
- Cefpirome**, against *Staphylococcus aureus*, 12
Cefpodoxime proxetil
 against *Staphylococcus aureus*, 126-127
 against *Staphylococcus epidermidis*, 126-127
 against *Staphylococcus* spp., 123-129
 against *Staphylococcus warneri*, 126-127
- Ceftazidime**
 against *Acinetobacter calcoaceticus*, 199
 against *Bacteroides fragilis*, 202
 against *Citrobacter freundii*, 196
 against coagulase-negative streptococci, 193
 endotoxin release and, 185-189
 against *Enterobacter aerogenes*, 196
 against *Enterobacter cloacae*, 196
 against *Enterococcus* spp., 194
 against *Escherichia coli*, 196
 against Gram-negative bacilli, 248
 against *Haemophilus influenzae*, 201
 against *Haemophilus parainfluenzae*, 201
 against *Klebsiella oxytoca*, 197
 against *Klebsiella pneumoniae*, 197
 against *Moraxella catarrhalis*, 201
 against *Morganella morganii*, 197
 against *Neisseria gonorrhoeae*, 202
 against *Neisseria* spp., 202
 against *Prevotella bivia-disiens*, 202
 against *Proteus mirabilis*, 197
 against *Proteus vulgaris*, 198
 against *Providencia rettgeri*, 198
 against *Providencia stuartii*, 198
 against *Pseudomonas aeruginosa*, 199
 against *Salmonella* spp., 198
 against *Serratia marcescens*, 199
 against *Shigella* spp., 199
 against *Staphylococcus aureus*, 12, 192-193
 against *Streptococcus agalactiae*, 193
 against *Streptococcus pneumoniae*, 194
 against *Streptococcus pyogenes*, 193
 against *Streptococcus*, viridans group, 194
 in teicoplanin fluorescence polarization immunoassay, 21
- Ceftriaxone**
 against *Acinetobacter calcoaceticus*, 199
 against *Bacteroides fragilis*, 202
 against *Citrobacter diversus*, 195
 against *Citrobacter freundii*, 196
 against coagulase-negative streptococci, 193
 against *Enterobacter aerogenes*, 196
 against *Enterobacter cloacae*, 196
 against *Enterococcus* spp., 194
 against *Escherichia coli*, 196
 against Gram-negative bacilli, 248
 against *Haemophilus ducreyi*, 116
 against *Haemophilus influenzae*, 200, 249
 against *Haemophilus parainfluenzae*, 201
 against *Klebsiella oxytoca*, 197
 against *Klebsiella pneumoniae*, 197
 against *Moraxella catarrhalis*, 201
 against *Morganella morganii*, 197
 against *Neisseria gonorrhoeae*, 116, 202
 against *Neisseria* spp., 202
 against *Prevotella bivia-disiens*, 202
 against *Proteus mirabilis*, 197
 against *Proteus vulgaris*, 198
 against *Providencia rettgeri*, 198
 against *Providencia stuartii*, 198
 against *Pseudomonas aeruginosa*, 199
 against *Salmonella* spp., 198
 against *Serratia marcescens*, 199
 against *Shigella* spp., 199
 against *Staphylococcus aureus*, 12, 192-193
 against *Streptococcus agalactiae*, 193
 against *Streptococcus pneumoniae*, 194
 against *Streptococcus pyogenes*, 193
 against *Streptococcus*, viridans group, 194
 in teicoplanin fluorescence polarization immunoassay, 21
- Cefuroxime**
 against *Acinetobacter calcoaceticus*, 199
 against *Bacteroides fragilis*, 202
 against *Citrobacter diversus*, 195
 against *Citrobacter freundii*, 196
 against coagulase-negative streptococci, 193
 against *Enterobacter aerogenes*, 196
 against *Enterobacter cloacae*, 196
 against *Enterococcus* spp., 194
 against *Escherichia coli*, 196
 against Gram-negative bacilli, 248
 against *Haemophilus influenzae*, 200, 249
 against *Haemophilus parainfluenzae*, 201
 against *Klebsiella oxytoca*, 197
 against *Klebsiella pneumoniae*, 197
 against *Moraxella catarrhalis*, 201
 against *Morganella morganii*, 197
 against *Neisseria gonorrhoeae*, 202
 against *Neisseria* spp., 202
 against *Prevotella bivia-disiens*, 202
- Cefoxitin**
 against *Citrobacter diversus*, 196
 against coagulase-negative streptococci, 193
 against *Enterococcus* spp., 194
 against Gram-negative bacilli, 248
 against *Staphylococcus aureus*, 192
 against *Streptococcus agalactiae*, 193
 against *Streptococcus pneumoniae*, 194
 against *Streptococcus pyogenes*, 193
 against *Streptococcus*, viridans group, 193
 in teicoplanin fluorescence polarization immunoassay, 21

- against *Proteus mirabilis*, 197
 against *Proteus vulgaris*, 198
 against *Providencia rettgeri*, 198
 against *Providencia stuartii*, 198
 against *Pseudomonas aeruginosa*, 199
 against *Salmonella* spp., 198
 against *Serratia marcescens*, 199
 against *Shigella* spp., 199
 against *Staphylococcus aureus*, 12, 192-193
 against *Streptococcus agalactiae*, 193
 against *Streptococcus pneumoniae*, 194
 against *Streptococcus pyogenes*, 193
 against *Streptococcus*, viridans group, 194
 Central nervous system (CNS), in clarithromycin therapy, 215-221
 Cephalosporins
 Bronx Municipal Hospital Center cascade of, 240
 against *Staphylococcus aureus*, 12
 Cephalothin
 against *Gemella morbillorum*, 131
 against Gram-negative bacilli, 248
 against *Streptococcus* spp., 248
 in teicoplanin fluorescence polarization immunoassay, 21
 Cephaphrin, in teicoplanin fluorescence polarization immunoassay, 21
 Cervicitis, mucopurulent, Centers for Disease Control 1991 estimates of, 174
 Checkerboard dilution test, for synergy, 343-349
 Chemiluminescent DNA probes, in detection of oxacillin resistance in *Staphylococcus aureus*, 99-104
 Children, respiratory syncytial virus in, 105-109
Chilomastix mesnili
 conventional microscopic examination for, 339
 ELISA for, 339
Chlamydia trachomatis
 Centers for Disease Control 1991 estimates of, 174
 direct detection of, 174-177
 rifaximin against, 135-136
 Chloramphenicol
 endotoxin release and, 185-189
 against *Gemella morbillorum*, 132
 against *Haemophilus influenzae*, 249
 against *Klebsiella pneumoniae*, 25-29
 against *Staphylococcus aureus*, 13
 in teicoplanin fluorescence polarization immunoassay, 21
 Chlortetracycline, in teicoplanin fluorescence polarization immunoassay, 21
 Cholesterol, abnormal levels of, in teicoplanin recovery, 17-24
 CI-960 (PD127391)
 against *Mycobacterium avium-intracellulare*, 351
 against *Mycobacterium chelonae-fortuitum*, 351
 against *Staphylococcus aureus*, 9-16
 Ciprofloxacin
 against *Campylobacter jejuni-coli*, 137-139
 against *Citrobacter freundii*, 138
 endotoxin release and, 185-189
 against *Enterobacter cloacae*, 138
 against enterococci, 83-85, 137-139, 248
 against *Escherichia coli*, 138, 277-289
 against Gram-negative bacilli, 248
 against *Haemophilus ducreyi*, 116
 against *Haemophilus influenzae*, 249
 against *Helicobacter pylori*, 114
 against *Klebsiella oxytoca*, 138
 against *Klebsiella pneumoniae*, 138
 against *Morganella morganii*, 138
 against *Mycobacterium avium-intracellulare* complex, 114, 351
 against *Mycobacterium chelonae-fortuitum*, 114, 351
 against *Mycoplasma hominis*, 114
 against *Proteus mirabilis*, 138
 against *Proteus penneri*, 138
 against *Proteus vulgaris*, 138
 against *Providencia stuartii*, 138
 against *Pseudomonas aeruginosa*, 137-139, 277-289
 against *Salmonella enterica*, 137
 against *Salmonella typhimurium*, 277-289
 against *Serratia marcescens*, 138
 against *Shigella* spp., 137
 against *Staphylococcus aureus*, 12, 277-289
 against *Staphylococcus* spp., 210, 223-226, 248
 qualitative susceptibility tests and, 233-234
 quantitative MIC tests and, 233-234
 against *Yersinia enterocolitica*, 137
 against *Yersinia pseudotuberculosis*, 277-289
 against *Ureaplasma urealyticum*, 114
Citrobacter diversus
 cefazolin against, 196
 cefonicid against, 196
 cefoperazone against, 195
 cefotaxime against, 195
 cefotetan against, 195
 cefoxitin against, 196
 ceftizoxime against, 195
 ceftriaxone against, 195
 cefuroxime against, 195
 rifaximin against, 113
Citrobacter freundii
 ampicillin-sulbactam against, 196
 in bacteriuria, 94
 cefazolin against, 196
 cefonicid against, 196
 cefotetan against, 196
 cefoxitin against, 196
 ceftazidime against, 196
 ceftriaxone against, 196
 cefuroxime against, 196
 ciprofloxacin against, 138
 imipenem against, 196
 rifaximin against, 113
 ticarcillin-clavulanate against, 196
Citrobacter spp., in slide agglutination against commercial *Salmonella* polyvalent antiserum and antiprotein serum, 73-74
 Clarithromycin
 high-dose, in elderly, 215-221
 against staphylococci, 210
 Clindamycin
 against *Bacteroides bivius-disiens*, 116
 against *Gardnerella vaginalis*, 116
 against *Gemella morbillorum*, 131
 against *Lactobacillus* spp., 24
 against *Mobiluncus* spp., 116
 against *Staphylococcus aureus*, 13
 against *Staphylococcus* spp., 205-213, 248
 against *Streptococcus* spp., 248
Clostridium difficile
 molecular epidemiology in hospitals and, 303-311
 toxin assay, focal white blood cells and, 313-315
Clostridium spp., BacT/Alert blood culture system in assessment of, 33
 CMV. See Cytomegalovirus
 CNS. See Central nervous system
 Computer-delivered susceptibilities, automatic, 252
 Computer software support, in managing antimicrobial usage, 258, 263-264
 Cord factor, *Nocardia asteroides*, 291-301
 Corticosteroids, against miliary tuberculosis, 68
Corynebacterium sp., BacT/Alert blood culture system in assessment of, 33
 Cost information, reporting of, 252-253
 Cost savings, for antimicrobial usage, 260-262
 Creatinine clearance, in mycobacterial lung disease, 215-221
Cryptosporidium spp.
 conventional microscopic examination for, 339
 ELISA for, 339
 Cytomegalovirus (CMV), human, rapid measurement of serum-neutralizing activity against, 75-77
 Cytoplasmic extract antigens, from *Nocardia asteroides*, 291-301
 Daptomycin
 against coagulase-negative staphylococci, 224
 against *Staphylococcus aureus*, 224
 Decaplanin, against *Staphylococcus aureus*, 12
 DFA. See Direct fluorescent antibody
 Diabetes, invasive candidiasis associated with, 57
 Diagnostic molecular microbiology, current challenges and future directions in, 159-163
Dientamoeba fragilis
 conventional microscopic examination for, 339
 ELISA for, 339
 Digoxin, in teicoplanin fluorescence polarization immunoassay, 21
 Dilution, automated, trends in, 232
 Diphtheroid, BacT/Alert blood culture system in assessment of, 33
 Direct fluorescent antibody (DFA), for respiratory syncytial virus, 325-329
 Dirithromycin, against staphylococci, 210
 Disk diffusion susceptibility testing of *Klebsiella oxytoca*, 35-41

- of *Klebsiella pneumoniae*, 35-41
- of quinolone-resistant *Staphylococcus aureus* strains, 9-16
- trends in, 232
- DNA restriction fragment analysis, in *Serratia marcescens* assessment, 1-7
- Dose-response studies, in animal infection models, 231-236
- Doxycycline
 - against *Mycoplasma hominis*, 114, 19
 - against *Ureaplasma urealyticum*, 114
- E-1040, against *Staphylococcus aureus*, 12
- Ear, *Serratia marcescens* in, 5
- Edwardsiella tarda*, in slide agglutination
 - against commercial *Salmonella* polyvalent antiserum and antiprotein serum, 73-74
- EIA. See Enzyme immunoassay
- Elderly, high-dose clarithromycin intolerance in, 215-221
- ELISA. See Enzyme-linked immunosorbent assay
- Empiric therapy, recommending, 253
- Endolimax nana*
 - conventional microscopic examination for, 339
 - ELISA for, 339
- Endotoxin, release of during antibiotic action, 185-189
- Endovascular infection, *Gemella morbillorum* in, 131-134
- Enoxacin
 - against enterococci, 83-85
 - against *Escherichia coli*, 277-289
 - against *Pseudomonas aeruginosa*, 277-289
 - against *Salmonella typhimurium*, 277-289
 - against *Staphylococcus aureus*, 12, 277-289
 - against *Yersinia pseudotuberculosis*, 277-289
- Entamoeba coli*
 - conventional microscopic examination for, 339
 - ELISA for, 339
- Entamoeba hartmanni*
 - conventional microscopic examination for, 339
 - ELISA for, 339
- Entamoeba histolytica*
 - conventional microscopic examination for, 339
 - ELISA for, 339
- Enterobacter aerogenes*
 - ampicillin-sulbactam against, 196
 - cefazolin against, 196
 - cefonicid against, 196
 - cefotetan against, 196
 - cefoxitin against, 196
 - ceftazidime against, 196
 - ceftriaxone against, 196
 - cefuroxime against, 196
 - imipenem against, 196
 - rifaximin against, 113
 - ticarcillin-clavanulate against, 196
- Enterobacter agglomerans*, rifaximin against, 113
- Enterobacter cloacae*
 - ampicillin-sulbactam against, 196
 - BacT/Alert blood culture system in assessment of, 33
 - cefazolin against, 196
 - cefonicid against, 196
 - cefotetan against, 196
 - cefoxitin against, 196
 - ceftazidime against, 196
 - ceftriaxone against, 196
 - cefuroxime against, 196
 - ciprofloxacin against, 138
 - endotoxin release and, 185-189
 - imipenem against, 196
 - rifaximin against, 113
 - ticarcillin-clavanulate against, 196
- Enterobacteriaceae
 - quinolones against, 137-139
 - rifaximin against, 113
- Enterobacter* spp., in slide agglutination
 - against commercial *Salmonella* polyvalent antiserum and antiprotein serum, 73-74
- Enterobius vermicularis*
 - conventional microscopic examination for, 339
 - ELISA for, 339
- Enterococci
 - ciprofloxacin against, 83-85
 - enoxacin against, 83-85
 - fleroxacin against, 83-85
 - fluoroquinolones against, 83-85
 - gentamicin against, 119-122, 148
 - high-level aminoglycoside resistance among, 119-122, 145-148
 - lomefloxacin against, 83-85
 - norfloxacin against, 83-85
 - ofloxacin against, 83-85
 - sparfloxacin against, 83-85
 - species identification of, 119-122
 - streptomycin against, 119-122, 145-148
 - temafloxacin against, 83-85
 - WIN57273 against, 83-85
- Enterococci, group D
 - PathoDx reagents for typing of, 89-91
 - Streptex reagents for typing of, 89-91
- Enterococcus avium*
 - high-level aminoglycoside resistance among, 145-148
 - identification of, 121
- Enterococcus casseliflavus*, identification of, 121
- Enterococcus durans*, identification of, 121
- Enterococcus faecalis*
 - ciprofloxacin against, 84
 - enoxacin against, 84
 - fleroxacin against, 84
 - high-level aminoglycoside resistance among, 119-122, 145-148
 - identification of, 119-122
 - lomefloxacin against, 84
 - norfloxacin against, 84
 - ofloxacin against, 84
 - PathoDx reagents for typing of, 89-91
 - rifaximin against, 113
 - sparfloxacin against, 84
 - Streptex reagents for typing of, 89-91
 - temafloxacin against, 84
 - WIN57273 against, 84
- Enterococcus faecium*
 - ciprofloxacin against, 84
 - enoxacin against, 84
 - fleroxacin against, 84
 - high-level aminoglycoside resistance among, 119-122, 145-148
 - identification of, 119-122
 - lomefloxacin against, 84
 - molecular epidemiology in hospitals and, 310
 - norfloxacin against, 84
 - ofloxacin against, 84
 - PathoDx reagents for typing of, 89-91
 - rifaximin against, 113
 - sparfloxacin against, 84
 - Streptex reagents for typing of, 89-91
 - temafloxacin against, 84
 - WIN57273 against, 84
- Enterococcus gallinarum*, identification of, 121
- Enterococcus hirae*, identification of, 121
- Enterococcus mundtii*, identification of, 121
- Enterococcus* spp.
 - in bacteriuria, 94
 - ampicillin against, 248
 - ampicillin-sulbactam against, 194
 - cefazolin against, 194
 - cefonicid against, 194
 - cefoperazone against, 194
 - cefotaxime against, 194
 - cefotetan against, 194
 - cefoxitin against, 194
 - ceftazidime against, 194
 - ceftizoxime against, 194
 - ceftriaxone against, 194
 - cefuroxime against, 194
 - ciprofloxacin against, 248
 - gentamicin against, 248
 - imipenem against, 194
 - ofloxacin against, 248
 - penicillin against, 248
 - rifaximin against, 111-118
 - streptomycin against, 248
 - ticarcillin-clavanulate against, 194
 - vancomycin against, 248
- Enteromonas hominis*
 - conventional microscopic examination for, 339
 - ELISA for, 339
- Enzyme immunoassay (EIA)
 - for *Helicobacter pylori*, 317-320
 - for HIV-1 antibodies, 331-335
 - for invasive candidiasis, 53-60
 - for respiratory syncytial virus, 325-329
- Enzyme-linked immunosorbent assay (ELISA)
 - for cytomegalovirus, 75-77
 - for *Giardia lamblia*, 337-341
 - in murine model for recognition of nocardial infections, 291-301
- Ephedrine, in teicoplanin fluorescence polarization immunoassay, 21
- m*-Erythritol, in *Serratia marcescens* biotyping system, 2-3

- Erythromycin**
 against *Gemella morbillorum*, 131
 against *Mycoplasma hominis*, 114
 against *Staphylococcus aureus*, 13
 against *Staphylococcus* spp., 205-213, 223-226, 248
 against *Streptococcus* spp., 248
 against *Ureaplasma urealyticum*, 114
 in teicoplanin fluorescence polarization immunoassay, 21
- Escherichia coli**
 ampicillin-sulbactam against, 197
 BacT/Alert blood culture system in assessment of, 33
 in bacteriuria, 94
 cefazolin against, 196
 cefonicid against, 196
 cefotetan against, 196
 cefoxitin against, 196
 ceftazidime against, 196
 ceftriaxone against, 196
 cefuroxime against, 196
 ciprofloxacin against, 138, 277-289
 cross-reactive antibodies between *Borrelia burgdorferi* and, 43-51
 endotoxin release and, 185-189
 enoxacin against, 277-289
 imipenem against, 196
 lomefloxacin against, 277-289
 quinolones against, 277-289
 rifaximin against, 113
 R-plasmids in, 25-29
 ticarcillin-clavulanate against, 197
- Ethambutol**
 against miliary tuberculosis, 68
 against *Mycobacterium avium*-intracellulare complex, 114, 351
 against *Mycobacterium chelonae*-fortuitum, 114, 351
 against unusual mycobacteria, 322-323
- Eye, Serratia marcescens** in, 5
- Fecal leukocyte test**, in *Clostridium difficile* toxin assay, 313-315
- FIC. See** Fractional inhibitory concentration
- Fingerprinting**, of microbial isolates, 153-157
- FITC. See** Fluorescein isothiocyanate
- Flagged results**, of susceptibility tests, 252
- FlashTrack probe assay**, in detection of oxacillin resistance in *Staphylococcus aureus*, 99-104
- Fleroxacin**
 against enterococci, 83-85
 against *Staphylococcus aureus*, 12
- Fluorescein isothiocyanate (FITC) conjugate-labeled monoclonal antibody typing reagent**, for herpes simplex virus detection, 87-88
- Fluorescence polarization immunoassay (FPIA)**, for teicoplanin in serum, 17-24
- Fluoroquinolones**
 against enterococci, 83-85
 against *Staphylococcus aureus*, 9-16
- Formulary control**, of antimicrobial usage, 265-274
- FPIA. See** Fluorescence polarization immunoassay
- Fractional inhibitory concentration (FIC)**, in checkerboard dilution test, 343-349
- Fungemia, BacT/Alert blood culture system** in assessment of, 31-34
- Furosemide**, in teicoplanin fluorescence polarization immunoassay, 21
- Fusobacterium* sp., BacT/Alert blood culture system in assessment of, 33
- Gallbladder, Serratia marcescens** in, 5
- Gardnerella vaginalis**
 ampicillin against, 116
 clindamycin against, 116
 metronidazole against, 116
 rifaximin against, 111-118
- Gastrointestinal bleeding, invasive candidiasis** associated with, 57
- Gemella morbillorum**
 ampicillin against, 132
 cephalothin against, 131
 chloramphenicol against, 132
 clindamycin against, 131
 in endovascular infection, 131-134
 erythromycin against, 131
 gentamicin against, 131-132
 penicillin against, 131-132
 rifampin against, 132
 in septic arthritis, 131-134
 streptomycin against, 132
 vancomycin against, 131-132
- Genital herpes, Centers for Disease Control 1991 estimates** of, 174
- Gen-Probe PACE II**
 for *Chlamydia trachomatis*, 174-176
 for *Neisseria gonorrhoeae*, 177-179
- Gentamicin**
 endotoxin release and, 185-189
 against enterococci, 119-122, 145-148, 248
 against *Gemella morbillorum*, 131-132
 against Gram-negative bacilli, 248
 against *Klebsiella pneumoniae*, 25-29
 against miliary tuberculosis, 67
 qualitative susceptibility tests and, 235
 quantitative MIC tests and, 235
 against staphylococci, 210
 against *Staphylococcus aureus*, 12
 in teicoplanin fluorescence polarization immunoassay, 21
- Giardia lamblia**, ELISA for detection of, 337-341
- Glycopeptides**
 fluorescence polarization immunoassay for, 17-24
 against *Staphylococcus aureus*, 9-16
- Gonorrhea**
 Centers for Disease Control 1991 estimates of, 174
 confirmatory testing for, 178-180
- Gram-negative bacilli**
 amikacin against, 248
 aminoglycosides against, 233
 amoxicillin-clavulanic acid against, 248
 ampicillin against, 248
 ampicillin-sulbactam against, 248
- BacT/Alert blood culture system** in assessment of, 33
- β -lactam antibiotics** against, 195-199
- cefaclor against, 248
- cefazolin against, 248
- cefixime against, 248
- cefmetazole against, 248
- cefotaxime against, 248
- cefotetan against, 248
- cefoxitin against, 248
- ceftazidime against, 248
- ceftizoxime against, 248
- ceftriaxone against, 248
- cefuroxime against, 248
- cephadroxil against, 248
- cephalexin against, 248
- cephalothin against, 248
- cephradine against, 248
- ciprofloxacin against, 233, 248
- endotoxin release from, 185-189
- gentamicin against, 248
- mezlocillin against, 248
- ofloxacin against, 248
- piperacillin against, 248
- rifaximin against, 113
- ticarcillin-clavulanic acid against, 248
- trimethoprim-sulfamethoxazole against, 248
- Gram-positive cocci**
 BacT/Alert blood culture system in assessment of, 33
- β -lactam antibiotics** against, 192-194
- rifaximin against, 113
- Grimont biotyping system, modified**, in *Serratia marcescens* assessment, 1-7
- GUH-2 antigen, Nocardia asteroides**, 291-301
- Haemophilus ducreyi**
 aztreonam against, 116
 ceftriaxone against, 116
 ciprofloxacin against, 116
 imipenem against, 116
 rifaximin against, 111-118
- Haemophilus influenzae**
 amoxicillin-clavulanic acid against, 249
 ampicillin against, 249
 ampicillin-sulbactam against, 201, 249
 cefaclor against, 249
 cefazolin against, 200
 cefixime against, 249
 cefonicid against, 200
 cefotaxime against, 249
 cefotetan against, 200
 cefoxitin against, 200
 ceftazidime against, 201
 ceftriaxone against, 200, 249
 cefuroxime against, 200, 249
 chloramphenicol against, 249
 ciprofloxacin against, 249
 imipenem against, 201
 ofloxacin against, 249
 rifaximin against, 111-118
 ticarcillin-clavulanate against, 201
 trimethoprim-sulfamethoxazole against, 249

- Haemophilus parainfluenzae*
 ampicillin-sulbactam against, 201
 cefazolin against, 201
 cefonicid against, 201
 cefotetan against, 201
 cefoxitin against, 201
 ceftazidime against, 201
 ceftriaxone against, 201
 cefuroxime against, 201
 imipenem against, 201
 ticarcillin-clavanulate against, 201
- HBV. *See* Hepatitis B virus
- Helicobacter pylori*
 ciprofloxacin against, 114
 imipenem against, 114
 norfloxacin against, 114
 ofloxacin against, 114
 QuickVue test for, 317-320
 rifaximin against, 114
- Hemoglobin, abnormal levels of, in teicoplanin recovery, 17-24
- Heparin, in teicoplanin fluorescence polarization immunoassay, 21
- Hepatitis, invasive candidiasis associated with, 57
- Hepatitis B virus (HBV), Centers for Disease Control 1991 estimates of, 174
- Herpes simplex virus (HSV)
 fluorescein isothiocyanate conjugate-labeled monoclonal antibody typing reagent for detection of, 87-88
 rapid detection of, 61-66
- Herpesviruses
 acyclovir against, 114
 rifaximin against, 111-118
- High-performance liquid chromatography (HPLC), of teicoplanin, 17-24
- HIV-1. *See* Human immunodeficiency virus type 1
- Hookworm
 conventional microscopic examination for, 339
 ELISA for, 339
- Hospital epidemiology, molecular technology for, 153-157, 303-311
- Hospitalized patients, *Serratia marcescens* in, 1-7
- HPLC. *See* High-performance liquid chromatography
- HPV. *See* Human papillomavirus
- HSV. *See* Herpes simplex virus
- Human genome project, microbiologic spinoffs of, 161-162
- Human immunodeficiency virus type 1 (HIV-1)
 antibodies, enzyme immunoassays for, 331-335
 Centers for Disease Control 1991 estimates of, 174
 polymerase chain reaction in assessment of, 165-172
- Human papillomavirus (HPV)
 Centers for Disease Control 1991 estimates of, 174
 hybridization assay in assessment of, 173-184
- Hybridization assays, in sexually transmitted disease assessment, 173-184
- Hybritech ICON *Candida* assay, for invasive candidiasis diagnosis, 53-60
- 3-Hydroxybenzoate, in *Serratia marcescens* biotyping system, 2-3
- 4-Hydroxybenzoate, in *Serratia marcescens* biotyping system, 2-3
- ICON *Candida* assay, for invasive candidiasis diagnosis, 53-60
- IFA. *See* Indirect immunofluorescent antibody
- IgG immunoassay
 cytomegalovirus-specific, 75-77
 for *Helicobacter pylori* antibodies, 317-320
- IgM immunoassay, for Lyme disease diagnosis, 43-51
- Imipenem
 against *Acinetobacter calcoaceticus*, 199
 against *Bacteroides fragilis*, 202
 against *Citrobacter freundii*, 196
 against coagulase-negative streptococci, 193
 endotoxin release and, 185-189
 against *Enterobacter aerogenes*, 196
 against *Enterobacter cloacae*, 196
 against *Enterococcus* spp., 194
 against *Escherichia coli*, 196
 against *Haemophilus ducreyi*, 116
 against *Haemophilus influenzae*, 201
 against *Haemophilus parainfluenzae*, 201
 against *Helicobacter pylori*, 114
 against *Klebsiella oxytoca*, 197
 against *Klebsiella pneumoniae*, 197
 against *Moraxella catarrhalis*, 201
 against *Morganella morganii*, 197
 against *Neisseria gonorrhoeae*, 202
 against *Neisseria* spp., 202
 against *Prevotella bivia-disiens*, 202
 against *Proteus mirabilis*, 197
 against *Proteus vulgaris*, 198
 against *Providencia rettgeri*, 198
 against *Providencia stuartii*, 198
 against *Pseudomonas aeruginosa*, 199
 against *Salmonella* spp., 198
 against *Serratia marcescens*, 199
 against *Shigella* spp., 199
 against *Staphylococcus aureus*, 12, 192-193
 against *Streptococcus agalactiae*, 193, 281
 against *Streptococcus pneumoniae*, 194
 against *Streptococcus pyogenes*, 193
 against *Streptococcus viridans* group, 194
- Immunofluorescence, in detection of respiratory syncytial virus, 105-109
- Indirect immunofluorescent antibody (IFA), in murine model for recognition of nocardial infections, 291-301
- Infectious diseases, book review on, 149-150
- In vitro amplification, false positives due to carryover of amplification products and, 159-161
- Iodamoeba bütschlii*
 conventional microscopic examination for, 339
 ELISA for, 339
- Isepamicin
 against *Mycobacterium avium-intracellulare*, 351
 against *Mycobacterium chelonae-fortuitum*, 351
- Isolator lysis-centrifugation system, in isolation of *Brucella* spp., 79-81
- Isoniazid
 against miliary tuberculosis, 68-69
 against *Mycobacterium avium-intracellulare* complex, 114, 351
 against *Mycobacterium chelonae-fortuitum*, 114, 351
 against unusual mycobacteria, 322-323
- Isoproterenol, in teicoplanin fluorescence polarization immunoassay, 21
- Jackson-Pratt drainage, *Serratia marcescens* in, 5
- Josamycin, against staphylococci, 208
- Kallestad Pathfinder enzyme immunoassay, for respiratory syncytial virus, 325-329
- Kanamycin
 against *Mycobacterium avium-intracellulare*, 351
 against *Mycobacterium chelonae-fortuitum*, 351
 in teicoplanin fluorescence polarization immunoassay, 21
- Klebsiella oxytoca*
 ampicillin-sulbactam against, 197
 in bacteriuria, 94
 biotyping of, 35-41
 cefazolin against, 197
 cefonicid against, 197
 cefotetan against, 197
 cefoxitin against, 197
 ceftazidime against, 197
 ceftriaxone against, 197
 cefuroxime against, 197
 ciprofloxacin against, 138
 disk diffusion susceptibility testing of, 35-41
 imipenem against, 197
 plasmid DNA analysis of, 35-41
 rifaximin against, 113
 subtyping tests for, 35-41
 ticarcillin-clavanulate against, 197
- Klebsiella pneumoniae*
 ampicillin against, 25-29
 ampicillin-sulbactam against, 197-198
 in bacteriuria, 94
 biotyping of, 35-41
 cefazolin against, 197
 cefonicid against, 197
 cefotetan against, 197
 cefoxitin against, 197
 ceftazidime against, 197
 ceftriaxone against, 197
 cefuroxime against, 197
 chloramphenicol against, 25-29
 ciprofloxacin against, 138
 disk diffusion susceptibility testing of, 35-41
 endotoxin release and, 185-189

- gentamicin against, 25-29
 imipenem against, 197
 piperacillin against, 25-29
 plasmid DNA analysis of, 35-41
 rifaximin against, 113
 R-plasmids in, 25-29
 subtyping tests for, 35-41
 tetracycline against, 25-29
 ticarcillin-clavanulate against, 197
 tobramycin against, 25-29
 trimethoprim-sulfamethoxazole against, 25-29
- Lactobacillus* spp.
 ampicillin against, 116
 clindamycin against, 116
 metronidazole against, 116
 rifaximin against, 111-118
- Lactose, in *Serratia marcescens* biotyping system, 2-3
- Leg, *Serratia marcescens* in, 5
- Leptospira interrogans*, cross-reactive antibodies between *Borrelia burgdorferi* and, 43-51
- Leukocyte esterase-nitrite strip, for bacteriuria, 93-97
- Leukocytes, fecal, in *Clostridium difficile* toxin assay, 313-315
- Ligase chain reaction, for HIV-1, 165-172
- Lincosamide resistance, among staphylococcal isolates, 205-213
- Liver enzymes, after clarithromycin therapy, 215-221
- LMD/Seradyn ELISA, for *Giardia lamblia*, 337-341
- Lomefloxacin
 against enterococci, 83-85
 against *Escherichia coli*, 277-289
 against *Pseudomonas aeruginosa*, 277-289
 against *Salmonella typhimurium*, 277-289
 against *Staphylococcus aureus*, 12, 277-289
 against *Yersinia pseudotuberculosis*, 277-289
- Lung cancer, invasive candidiasis associated with, 57
- Lung disease, mycobacterial, clarithromycin against, 215-221
- Lupus, invasive candidiasis associated with, 57
- Lyme disease, laboratory diagnosis of, 43-51
- Lymphoma, invasive candidiasis associated with, 57
- Lysis-centrifugation procedure, in isolation of *Brucella* spp., 79-81
- Macrolide-lincosamide-streptogramin resistance, among staphylococcal isolates, 205-213
- Mannan antigenemia, invasive candidiasis and, 53-60
- MBCs. See Minimum bactericidal concentrations
- MDL-62211, against *Staphylococcus aureus*, 12
- MDL-62873, against *Staphylococcus aureus*, 12
- Medical technologists, using molecular epidemiology as part of infection control team, 303-311
- Men, sexually transmitted diseases in, 180-182
- Methicillin
Staphylococcus aureus against, 303-311
 in teicoplanin fluorescence polarization immunoassay, 21
- Methylene blue stain, in *Clostridium difficile* toxin assay, 313-315
- Metronidazole
 against *Bacteroides bivius*-*disiens*, 116
 against *Gardnerella vaginalis*, 116
 against *Lactobacillus* spp., 24
 against *Mobiluncus* spp., 116
- Mezlocillin, against Gram-negative bacilli, 248
- MICs. See Minimum inhibitory concentrations
- Miliary tuberculosis, unusual presentation of, 67-71
- Minimum bactericidal concentrations (MBCs)
 ampicillin, 132
 ampicillin-sulbactam, 186
 aztreonam, 186
 ceftazidime, 186
 chloramphenicol, 132, 186
 ciprofloxacin, 186
 gentamicin, 132, 186
 imipenem, 186
 L-ofloxacin, 186
 penicillin, 131-132
 rifampin, 132
 streptomycin, 132
 temofloxacin, 186
 vancomycin, 131-132
- Minimum inhibitory concentrations (MICs)
 acyclovir, 114
 amikacin, 114, 235
 aminoglycosides, 233
 ampicillin, 116, 132
 ampicillin-sulbactam, 186
 azithromycin, 210
 aztreonam, 116, 186
 cefaclor, 123-129
 cefmenoxime, 233, 234
 cefpodoxime proxetil, 123-129
 ceftazidime, 186
 ceftriaxone, 116
 chloramphenicol, 132, 186
 ciprofloxacin, 114, 116, 137-139, 186, 210, 224-225, 233-234, 277-289
 clarithromycin, 210
 clindamycin, 116, 210
 daptomycin, 224
 dirithromycin, 210
 doxycycline, 114
 enoxacin, 277-289
 erythromycin, 114, 210, 224-225
 ethambutol, 114
 gentamicin, 132, 186, 210, 235
 imipenem, 114, 116, 186
 isoniazid, 114
 lomefloxacin, 277-289
- metronidazole, 116
- minocycline, 210
- norfloxacin, 114
- ofloxacin, 114
- L-ofloxacin, 186
- 14-OH clarithromycin, 210
- oxacillin, 103, 210, 224-225
- penicillin, 131-132
- qualitative susceptibility tests vs, 231-236
- quinolones, 277-289
- rifampin, 114, 132, 210
- rifaximin, 111-118, 135-136
- RP59500, 210, 223-226
- spiramycin, 224-225
- streptomycin, 132
- teicoplanin, 210, 224
- temofloxacin, 186
- tobramycin, 234-235
- tylosin, 210
- vancomycin, 131-132, 210, 224-225
- virginiamycin, 210
- Mink lung cells, in rapid detection of herpes simplex virus, 61-66
- Minocycline
 against staphylococci, 210
 against *Staphylococcus aureus*, 343-349
- Mobiluncus* spp.
 ampicillin against, 116
 clindamycin against, 116
 metronidazole against, 116
 rifaximin against, 111-118
- Molecular techniques, critical assessment of role of in clinical microbiology, 151-184
- Monitoring therapy, via nucleic acid amplification, 161
- Monoclonal antibodies
 in herpes simplex virus detection, 87-88
 in respiratory syncytial virus detection, 105-109
- Mononucleosis, infectious, sera from patients with in laboratory diagnosis of Lyme disease, 43-51
- Moraxella catarrhalis*
 ampicillin-sulbactam against, 201
 cefazolin against, 201
 cefonicid against, 201
 cefotetan against, 201
 cefoxitin against, 201
 ceftazidime against, 201
 ceftriaxone against, 201
 cefuroxime against, 201
 imipenem against, 201
 rifaximin against, 111-118
 ticarcillin-clavanulate against, 201
- Morganella morganii*
 cefazolin against, 197
 cefonicid against, 197
 cefotetan against, 197
 cefoxitin against, 197
 ceftazidime against, 197
 ceftriaxone against, 197
 cefuroxime against, 197
 ciprofloxacin against, 138
 imipenem against, 197
 rifaximin against, 113
 ticarcillin-clavanulate against, 197

- Mucous membranes, invasive candidiasis in, 53-60
- Multiple sclerosis, invasive candidiasis associated with, 57
- Mupirocin, against *Staphylococcus aureus*, 9-16
- Murine model, recognition of nocardial infections in, 291-301
- Mycobacteria, unusual, in AIDS, 321-323
- Mycobacterium abscessus*, in lung disease, 215-221
- Mycobacterium avium* complex
in lung disease, 215-221
in murine model for recognition of nocardial infections, 296, 299
- Mycobacterium avium-intracellulare* complex
amikacin against, 114, 351
CI-960 against, 351
ciprofloxacin against, 114, 351
ethambutol against, 114, 351
isepamicin against, 351
isoniazid against, 114, 351
kanamycin against, 351
norfloxacin against, 351
rifampin against, 114, 351
rifaximin against, 114
sparfloxacin against, 351
WIN57273 against, 351
- Mycobacterium chelonae-fortuitum*
amikacin against, 114, 351
CI-960 against, 351
ciprofloxacin against, 114, 351
ethambutol against, 114, 351
isepamicin against, 351
isoniazid against, 114, 351
kanamycin against, 351
norfloxacin against, 351
rifampin against, 114, 351
rifaximin against, 114
sparfloxacin against, 351
WIN 57273 against, 351
- Mycobacterium chelonae* spp. *abscessus*, in murine model for recognition of nocardial infections, 296-297, 299
- Mycobacterium fortuitum*, in murine model for recognition of nocardial infections, 297, 299-300
- Mycobacterium genavense*, in AIDS, 321-323
- Mycobacterium intracellulare*, in murine model for recognition of nocardial infections, 296, 299
- Mycobacterium kansasii*, in murine model for recognition of nocardial infections, 296, 299
- Mycobacterium paratuberculosis*, in murine model for recognition of nocardial infections, 296, 299
- Mycobacterium scrofulaceum*, in murine model for recognition of nocardial infections, 296, 299
- Mycobacterium* spp., in murine model for recognition of nocardial infections, 291-301
- Mycobacterium tuberculosis*
in miliary tuberculosis, 67-71
in murine model for recognition of nocardial infections, 296
- Mycoplasma hominis*
ciprofloxacin against, 114
doxycycline against, 114
erythromycin against, 114
rifaximin against, 114
- Mycoplasmas, rifaximin against, 111-118
- Nalidixic acid, against *Staphylococcus aureus*, 12
- NAP, against unusual mycobacteria, 322-323
- Nasal isolates
Serratia marcescens in, 5
Staphylococcus aureus in, 9-16
- National Committee for Clinical Laboratory Standards (NCCLS) microdilution tests, in assessment of aminoglycoside resistance, 145-148
- Nausea, in clarithromycin therapy, 215-221
- Neisseria gonorrhoeae*
ampicillin-sulbactam against, 202
cefazolin against, 202
cefonicid against, 202
cefotetan against, 202
cefoxitin against, 202
ceftazidime against, 202
ceftriaxone against, 116, 202
cefuroxime against, 202
direct detection of, 177-179
imipenem against, 202
rifaximin against, 111-118
ticarcillin-clavulanate against, 202
- Neisseria* spp.
ampicillin-sulbactam against, 202
cefazolin against, 202
cefonicid against, 202
cefotetan against, 202
cefoxitin against, 202
ceftazidime against, 202
ceftriaxone against, 202
cefuroxime against, 202
imipenem against, 202
rifaximin against, 113
ticarcillin-clavulanate against, 202
- Neomycin
against *Staphylococcus aureus*, 13
in teicoplanin fluorescence polarization immunoassay, 21
- Netilmicin, in teicoplanin fluorescence polarization immunoassay, 21
- Neurosurgery, invasive candidiasis associated with, 57
- Nitrofurantoin, against *Staphylococcus aureus*, 13
- Nocardia asteroides*, murine seroreactivity to, 291-301
- Nocardia brasiliensis*, murine seroreactivity to, 296, 300
- Nocardia caviae*, murine seroreactivity to, 296, 299-300
- Norfloxacin
against enterococci, 83-85
against *Helicobacter pylori*, 114
against *Mycobacterium avium-intracellulare*, 351
against *Mycobacterium chelonae-fortuitum*, 351
- against *Staphylococcus aureus*, 12
- Nosocomial infections
cefmenoxime against, 234
enterococci in, 119-122
- Novobiocin, against *Staphylococcus aureus*, 9-16
- Nucleic acid amplification techniques
current challenges and future directions in, 159-163
in sexually transmitted disease assessment, 173-184
- Ofloxacin
against enterococci, 83-85, 248
against Gram-negative bacilli, 248
against *Haemophilus influenzae*, 249
against *Helicobacter pylori*, 114
against *Staphylococcus aureus*, 12
against *Staphylococcus* spp., 248
against *Streptococcus* spp., 248
- L-Ofloxacin, endotoxin release and, 185-189
- 14-OH clarithromycin
high-dose, in elderly, 215-221
against staphylococci, 210
- Overnight testing, traditional, impact of, 237-243
- Oxacillin, against *Staphylococcus* spp., 9-16, 99-104, 210, 223-226, 248
- Oxytetracycline, in teicoplanin fluorescence polarization immunoassay, 21
- Parasites, rifaximin against, 111-118
- Passive intervention, problems of, 241-242
- PathoDx reagents
for group D typing of vancomycin-resistant *Enterococcus*, 89-91
for herpes simplex virus detection, 87-88
- PCR. See Polymerase chain reaction
- PD127391. See CI-960
- PD131618, against *Staphylococcus aureus*, 12
- Penicillin
against *Enterococcus* spp., 248
against *Gemella morbillorum*, 131-132
against *Staphylococcus* spp., 248
against *Streptococcus* spp., 248
- Penicillin G, in teicoplanin fluorescence polarization immunoassay, 21
- Peptide-based enzyme immunoassay, for HIV-1 antibodies, 331-335
- Peptone-glycerol agar, in *Serratia marcescens* biotyping system, 2
- Pericardial fluid, *Serratia marcescens* in, 5
- Perineal region, *Klebsiella pneumoniae* in, 25-29
- Pigment production, in *Serratia marcescens* biotyping system, 2-3
- Piperacillin
against Gram-negative bacilli, 248
against *Klebsiella pneumoniae*, 25-29
- Plaque reduction neutralization assay (PRNA), for rapid measurement of serum-neutralizing activity against human cytomegalovirus, 75-76
- Plasmid DNA analysis
in hospital epidemiology, 153-157
of *Klebsiella oxytoca*, 35-41
of *Klebsiella pneumoniae*, 35-41

- PMNs. *See* Polymorphonuclear leukocytes
- Pneumonia, nosocomial, cefmenoxine against, 234
- Polymerase chain reaction (PCR)
in *Chlamydia trachomatis* detection, 176
current challenges and future directions in, 159-163
of HIV-1, 165-172
- Polymorphonuclear leukocytes (PMNs)
Staphylococcus aureus phagocytosis by, 279-280
- Predictive susceptibilities, reporting, 253
- Prednisone, against miliary tuberculosis, 67
- Prevotella bivia*-*disiens*
ampicillin-sulbactam against, 202
cefazolin against, 202
cefonicid against, 202
cefotetan against, 202
cefoxitin against, 202
ceftazidime against, 202
ceftriaxone against, 202
cefuroxime against, 202
imipenem against, 202
ticarcillin-clavanulate against, 202
- PRNA. *See* Plaque reduction neutralization assay
- Propionibacterium* spp., BacT/Alert blood culture system in assessment of, 33
- Proteins, antigenic, of *Borrelia burgdorferi*, 43-51
- Proteus mirabilis*
in bacteriuria, 94
cefazolin against, 197
cefonicid against, 197
cefotetan against, 197
cefoxitin against, 197
ceftazidime against, 197
ceftriaxone against, 197
cefuroxime against, 197
ciprofloxacin against, 138
imipenem against, 197
rifaximin against, 113
ticarcillin-clavanulate against, 197
- Proteus penneri*, ciprofloxacin against, 138
- Proteus vulgaris*
cefazolin against, 198
cefonicid against, 198
cefotetan against, 198
cefoxitin against, 198
ceftazidime against, 198
ceftriaxone against, 198
cefuroxime against, 198
ciprofloxacin against, 138
imipenem against, 198
rifaximin against, 113
ticarcillin-clavanulate against, 198
- Providencia rettgeri*
ampicillin-sulbactam against, 198
cefazolin against, 198
cefonicid against, 198
cefotetan against, 198
cefoxitin against, 198
ceftazidime against, 198
ceftriaxone against, 198
cefuroxime against, 198
imipenem against, 198
rifaximin against, 113
ticarcillin-clavanulate against, 198
- Providencia stuartii*
ampicillin-sulbactam against, 198
cefazolin against, 198
cefonicid against, 198
cefotetan against, 198
cefoxitin against, 198
ceftazidime against, 198
ceftriaxone against, 198
cefuroxime against, 198
ciprofloxacin against, 138
imipenem against, 198
rifaximin against, 113
ticarcillin-clavanulate against, 198
- Pseudomonas aeruginosa*
ampicillin-sulbactam against, 199
in bacteriuria, 94
cefazolin against, 199
cefonicid against, 199
cefotetan against, 199
cefoxitin against, 199
ceftazidime against, 199
ceftriaxone against, 199
cefuroxime against, 199
ciprofloxacin against, 137-139, 277-289
endotoxin release and, 185-189
enoxacin against, 277-289
imipenem against, 199
lomefloxacin against, 277-289
quinolones against, 277-289
rifaximin against, 113
ticarcillin-clavanulate against, 199
- Pyogenic fascitis, miliary tuberculosis originally presenting as, 67-71
- Pyrazinamide
against miliary tuberculosis, 68
against unusual mycobacteria, 322-323
- Qualitative susceptibility tests, versus quantitative MIC tests, 231-236
- QuickVue test, for *Helicobacter pylori*, 317-320
- Quinolones
against Enterobacteriaceae, 137-139
against *Escherichia coli*, 277-289
against *Pseudomonas aeruginosa*, 277-289
against *Salmonella typhimurium*, 277-289
against *Staphylococcus aureus*, 9-16, 277-289
against *Yersinia pseudotuberculosis*, 277-289
- Ramoplanin, against *Staphylococcus aureus*, 9-16
- Rapid enzyme immunoassay test, for *Helicobacter pylori*, 317-320
- Rapid reporting, effects of, 239-240
- REAP profile, of *Staphylococcus aureus* strains, 9-16
- Recombinant protein-based enzyme immunoassay, for HIV-1 antibodies, 331-335
- Relative light units, in oxacillin susceptibility testing, 99-104
- Renal function, clarithromycin effect on, 215-221
- Respiratory syncytial virus (RSV)
Abbott TestPack RSV for diagnosis of, 105-109
Kallestad Pathfinder enzyme immunoassay for, 325-329
- Restriction endonuclease analysis
in hospital epidemiology, 153-157
of *Klebsiella oxytoca*, 35-41
of *Klebsiella pneumoniae*, 35-41
of quinolone-resistant *Staphylococcus aureus*, 9-16
of *Serratia marcescens*, 1-7
- Rheumatoid arthritis, sera from patients with, in laboratory diagnosis of Lyme disease, 43-51
- Rhodococcus equi*, in murine model for recognition of nocardial infections, 291-301
- Ribosomal RNA (rRNA), in *Staphylococcus aureus*, 99-104
- Rifampin
against *Gemella morbillorum*, 132
against miliary tuberculosis, 68
against *Mycobacterium avium*-intracellulare complex, 114, 351
against *Mycobacterium chelonae*-fortuitum, 114, 351
against staphylococci, 205-213
against *Staphylococcus aureus*, 343-349
in teicoplanin fluorescence polarization immunoassay, 21
against unusual mycobacteria, 322-323
- Rifamycin, rifaximin as derivative of, 111-118, 135-136
- Rifaximin
against *Acinetobacter* spp., 113
against *Bacillus cereus*, 111-118
against *Bacteroides bivius*-*disiens*, 111-118
against *Candida* spp., 111-118
against *Chlamydia trachomatis*, 135-136
against *Citrobacter diversus*, 113
against *Citrobacter freundii*, 113
against coagulase-negative staphylococci, 113
against *Enterobacter aerogenes*, 113
against *Enterobacter agglomerans*, 113
against *Enterobacter cloacae*, 113
against *Enterococcus faecalis*, 113
against *Enterococcus faecium*, 113
against *Enterococcus* spp., 111-118
against *Escherichia coli*, 113
against *Gardnerella vaginalis*, 111-118
against Gram-negative bacilli, 113
against Gram-positive organisms, 113
against *Haemophilus ducreyi*, 111-118
against *Haemophilus influenzae*, 111-118
against *Helicobacter pylori*, 114
against herpes virus, 111-118
against *Klebsiella oxytoca*, 110
against *Klebsiella pneumoniae*, 113
against *Lactobacillus* spp., 24, 111-118
against *Mobiluncus* spp., 111-118
against *Moraxella catarrhalis*, 111-118
against *Morganella morganii*, 113
against *Mycobacterium avium*-intracellulare complex, 114
against *Mycobacterium chelonae*-fortuitum, 114

- against *Mycoplasma hominis*, 114
 against mycoplasmas, 111-118
 against *Neisseria gonorrhoeae*, 111-118
 against *Neisseria* spp., 113
 against *Proteus mirabilis*, 113
 against *Proteus vulgaris*, 113
 against *Providencia rettgeri*, 113
 against *Providencia stuartii*, 113
 against *Pseudomonas aeruginosa*, 113
 against *Salmonella enteritidis*, 113
 against *Serratia marcescens*, 113
 against *Shigella* spp., 113
 against *Staphylococcus aureus*, 113
 against *Staphylococcus epidermidis*, 113
 against *Staphylococcus haemolyticus*, 113
 against *Staphylococcus* spp., 111-118
 against *Streptococcus pneumoniae*, 113
 against *Streptococcus* spp., 111-118
 against *Trichomonas vaginalis*, 111-118
 against *Ureaplasma urealyticum*, 111-118
 against *Xanthomonas maltophilia*, 113
 against *Yersinia enterocolitica*, 113
- Rocky Mountain spotted fever, sera from patients with, in laboratory diagnosis of Lyme disease, 43-51
- Roschka's vaccine, in *Salmonella* (A-E) polyvalent antiserum preparation, 73
- Routine testing, antimicrobial selection for, 245-249
- RP59500
 against coagulase-negative staphylococci, 223-226
 against staphylococci, 205-213
 against *Staphylococcus aureus*, 223-226
- R-plasmids, large, in spinal cord injury, 25-29
- rRNA. *See* Ribosomal RNA
- RSV. *See* Respiratory syncytial virus
- RU29246. *See* Cefdaloxine
- Salmonella* (A-E) polyvalent antiserum, simple preparation of, 73-74
- Salmonella arizonae*, in slide agglutination against commercial *Salmonella* polyvalent antiserum and antiprotein serum, 73-74
- Salmonella enterica*, ciprofloxacin against, 137
- Salmonella enteritidis*, rifaximin against, 113
- Salmonella paratyphi* A, in slide agglutination against commercial *Salmonella* polyvalent antiserum and antiprotein serum, 74
- Salmonella* spp.
 ampicillin-sulbactam against, 198
 cefazolin against, 198
 cefonicid against, 198
 cefotetan against, 198
 cefoxitin against, 198
 ceftazidime against, 198
 ceftriaxone against, 198
 cefuroxime against, 198
 imipenem against, 198
 in slide agglutination against commercial *Salmonella* polyvalent antiserum and antiprotein serum, 74
 ticarcillin-clavulanate against, 198
- Salmonella typhi*, in slide agglutination against commercial *Salmonella* polyvalent antiserum and antiprotein serum, 73-74
- Salmonella typhimurium*
 ciprofloxacin against, 277-289
 enoxacin against, 277-289
 lomefloxacin against, 277-289
 quinolones against, 277-289
 in slide agglutination against commercial *Salmonella* polyvalent antiserum and antiprotein serum, 74
- Same-day tests, impact of, 237-243
- Schistosoma mansoni*
 conventional microscopic examination for, 339
 ELISA for, 339
- Sepsis, BacT/Alert blood culture system in assessment of, 31-34
- Septic arthritis, *Gemella morbillorum* in, 131-134
- Serratia marcescens*
 ampicillin-sulbactam against, 199
 biotyping of, 1-7
 cefazolin against, 199
 cefonicid against, 199
 cefotetan against, 199
 cefoxitin against, 199
 ceftazidime against, 199
 ceftriaxone against, 199
 cefuroxime against, 199
 ciprofloxacin against, 138
 DNA restriction fragment analysis in study of, 1-7
 imipenem against, 199
 molecular epidemiology in hospitals and, 303-311
 rifaximin against, 113
 ticarcillin-clavulanate against, 199
- Serum, teicoplanin in, 17-24
- Sexually transmitted diseases (STDs), molecular diagnostics in, 173-184
- Shell vial culture
 for herpes simplex virus detection, 61-66
 for respiratory syncytial virus detection, 105-109
- Shigella* spp.
 ampicillin-sulbactam against, 199
 cefazolin against, 199
 cefonicid against, 199
 cefotetan against, 199
 cefoxitin against, 199
 ceftazidime against, 199
 ceftriaxone against, 199
 cefuroxime against, 199
 ciprofloxacin against, 137
 imipenem against, 199
 rifaximin against, 113
 ticarcillin-clavulanate against, 199
- Short-gut syndrome, invasive candidiasis associated with, 57
- SICU. *See* Surgical intensive care unit
- Skin infections
 cefaclor against, 123-129
 cefpodoxime proxetil against, 123-129
- SLE. *See* Systemic lupus erythematosus
- Sodium chloride, in *Serratia marcescens* biotyping system, 2
- Sodium tetrathionate, in *Serratia marcescens* biotyping system, 2-3
- Soft tissue infections
 cefaclor against, 123-129
 cefpodoxime proxetil against, 123-129
- Somatic cells, catalase activity in, 93-97
- D-Sorbitol, in *Serratia marcescens* biotyping system, 2
- Sparfloxacin
 against enterococci, 83-85
 against *Mycobacterium avium-intracellulare*, 351
 against *Mycobacterium chelonae-fortuitum*, 351
 against *Staphylococcus aureus*, 12
- Spectinomycin
 against staphylococci, 208
 in teicoplanin fluorescence polarization immunoassay, 21
- Spinal cord injury, in *Klebsiella pneumoniae* colonizing patients, 25-29
- Spiramycin, against staphylococci, 223-226
- Spirochetes, *Borrelia burgdorferi* protein cross-reactivity with, 43-51
- Sputum, *Serratia marcescens* in, 5
- Staphylococci
 azithromycin against, 205-213
 ciprofloxacin against, 223-226
 clindamycin against, 205-213
 erythromycin against, 205-213, 223-226
 josamycin against, 208
 macrolide-lincosamide-streptogramin resistances among, 205-213
 oxacillin against, 223-226
 rifampin against, 205-213
 RP59500 against, 205-213
 spectinomycin against, 208
 spiramycin against, 223-226
 vancomycin against, 205-213
 virginiamycin against, 205-213
- Staphylococci, coagulase-negative
 ampicillin-sulbactam against, 193
 BacT/Alert blood culture system in assessment of, 33
 in bacteriuria, 94
 cefazolin against, 193
 cefonicid against, 193
 cefoperazone against, 193
 cefotaxime against, 193
 cefotetan against, 193
 cefoxitin against, 193
 ceftazidime against, 193
 ceftizoxime against, 193
 ceftriaxone against, 193
 cefuroxime against, 193
 imipenem against, 193
 rifaximin against, 113
 RP59500 against, 223-226
 ticarcillin-clavulanate against, 193
- Staphylococcus aureus*
 ampicillin-sulbactam against, 192-193
 bacitracin against, 9-16
 in bacteriuria, 94
 cefaclor against, 126-127
 cefazolin against, 192, 248
 cefonicid against, 192
 cefoperazone against, 192-193
 cefotaxime against, 192-193

- cefotetan against, 192-193
 cefoxitin against, 192
 cefpodoxime proxetil against, 126-127
 ceftazidime against, 192-193
 ceftizoxime against, 192-193
 ceftriaxone against, 192-193
 cefuroxime against, 192-193
 CI-960 against, 9-16
 ciprofloxacin against, 248, 277-289
 clindamycin against, 248
 endotoxin release and, 185-189
 enoxacin against, 277-289
 erythromycin against, 248
 glycopeptides against, 9-16
 imipenem against, 192-193
 lomefloxacin against, 277-289
 macrolide-lincosamide-streptogramin
 resistance in, 205-213
 methicillin against, 303-311
 minocycline against, 343-349
 molecular epidemiology in hospitals and,
 303-311
 mupirocin against, 9-16
 novobiocin against, 9-16
 ofloxacin against, 248
 oxacillin against, 9-16, 99-104, 248
 penicillin against, 248
 quinolones against, 9-16, 277-289
 ramoplanin against, 9-16
 rifampin against, 343-349
 rifaximin against, 113
 RP59500 against, 223-226
 ticarcillin-clavanulate against, 192-193
 topical agents against, 9-16
 trimethoprim-sulfamethoxazole against,
 248
 vancomycin against, 248
 WIN57273 against, 9-16
Staphylococcus capitis, RP59500 against,
 226
Staphylococcus cohnii, RP59500 against,
 226
Staphylococcus epidermidis
 ceftazidime against, 126-127
 cefpodoxime proxetil against, 126-127
 macrolide-lincosamide-streptogramin
 resistance in, 205-213
 rifaximin against, 113
 RP59500 against, 226
Staphylococcus haemolyticus
 macrolide-lincosamide-streptogramin
 resistance in, 205-213
 rifaximin against, 113
 RP59500 against, 226
Staphylococcus hominis
 macrolide-lincosamide-streptogramin
 resistance in, 205-213
 RP59500 against, 226
Staphylococcus saprophyticus, RP59500
 against, 226
Staphylococcus sciuri, RP59500 against, 226
Staphylococcus simulans
 macrolide-lincosamide-streptogramin
 resistance in, 206, 209
 RP59500 against, 226
Staphylococcus spp.
 ceftazidime against, 123-129
 cefpodoxime proxetil against, 123-129
 macrolide-lincosamide-streptogramin
 resistance in, 205-213
 rifaximin against, 111-118
Staphylococcus warneri
 ceftazidime against, 126-127
 cefpodoxime proxetil against, 126-127
 macrolide-lincosamide-streptogramin
 resistance in, 206, 209-210
 RP59500 against, 226
 STDs. *See* Sexually transmitted diseases
 Stool specimens, ELISA for *Giardia lamblia*
 in, 337-341
 Streptex reagents, for group D typing of
 vancomycin-resistant *Enterococcus*,
 89-91
 Streptococci, β -hemolytic, BacT/Alert blood
 culture system in assessment of, 33
Streptococcus agalactiae
 ampicillin-sulbactam against, 193
 in bacteriuria, 94
 cefazolin against, 193
 cefonicid against, 193
 cefoperazone against, 193
 cefotaxime against, 193
 cefotetan against, 193
 cefoxitin against, 193
 ceftazidime against, 193
 ceftizoxime against, 193
 ceftriaxone against, 193
 cefuroxime against, 193
 imipenem against, 193
 ticarcillin-clavanulate against, 193
Streptococcus pneumoniae, rifaximin against,
 113
Streptococcus pyogenes
 ampicillin-sulbactam against, 193
 cefazolin against, 193
 cefonicid against, 193
 cefoperazone against, 193
 cefotaxime against, 193
 cefotetan against, 193
 cefoxitin against, 193
 ceftazidime against, 193
 ceftizoxime against, 193
 ceftriaxone against, 193
 cefuroxime against, 193
 imipenem against, 193
 ticarcillin-clavanulate against, 193
Streptococcus spp.
 ampicillin-sulbactam against, 194
 cefazolin against, 194, 248
 cefonicid against, 194
 cefoperazone against, 194
 cefotaxime against, 194
 cefotetan against, 194
 cefoxitin against, 194
 ceftazidime against, 194
 ceftizoxime against, 194
 ceftriaxone against, 194
 cefuroxime against, 194
 cephalothin against, 248
 clindamycin against, 248
 erythromycin against, 248
 imipenem against, 194
 ofloxacin against, 248
 penicillin against, 248
 rifaximin against, 111-118
 ticarcillin-clavanulate against, 194
 vancomycin against, 248
Streptococcus, viridans group
 ampicillin-sulbactam against, 194
 cefazolin against, 193
 cefonicid against, 193
 cefoperazone against, 194
 cefotaxime against, 194
 cefotetan against, 194
 cefoxitin against, 193
 ceftazidime against, 194
 ceftizoxime against, 194
 ceftriaxone against, 194
 cefuroxime against, 194
 imipenem against, 194
 ticarcillin-clavanulate against, 194
 Streptogramins, against staphylococci,
 205-213, 223-226
Streptomyces ramosus, in murine model for
 recognition of nocardial infections,
 297, 299
Streptomyces somaliensis, in murine model for
 recognition of nocardial infections,
 297, 299
 Streptomycin
 against enterococci, 119-122, 145-148, 248
 against *Gemella morbillorum*, 132
 against miliary tuberculosis, 68
 in teicoplanin fluorescence polarization
 immunoassay, 21
 against unusual mycobacteria, 322-323
 Stroke, invasive candidiasis associated with,
 57
Strongyloides spp.
 conventional microscopic examination
 for, 339
 ELISA for, 339
 Sulfadiazine, in teicoplanin fluorescence
 polarization immunoassay, 21
 Sulfamethoxazole, in teicoplanin fluores-
 cence polarization immunoassay, 21
 Surgical intensive care unite (SICU), *Serratia*
 marcescens in, 1-7
 Susceptibility test results, reporting of, 239-
 240, 251-254
 Suspension-infection method, rapid detec-
 tion of for herpes simplex virus, 61-66
 Synergy, checkerboard for, 343-349
 Syphilis
 Centers for Disease Control 1991 esti-
 mates of, 174
 secondary, in laboratory diagnosis of
 Lyme disease, 43-51
 Systemic lupus erythematosus (SLE), in
 laboratory diagnosis of Lyme disease,
 43-51
 TCH. *See* Thiophene carboxylic acid hydra-
 zide
 Teicoplanin
 against coagulase-negative staphylococci,
 224
 fluorescence polarization immunoassay
 for, 17-24
 against staphylococci, 210
 against *Staphylococcus aureus*, 12, 224
 Temafloxacin
 endotoxin release and, 185-189
 against enterococci, 83-85

- Tenosynovitis, miliary tuberculosis originally presenting as, 67-71
- Tetracycline
 against *Klebsiella pneumoniae*, 25-29
 against *Staphylococcus aureus*, 13
 in teicoplanin fluorescence polarization immunoassay, 21
- Tetrathionate reduction, in *Serratia marcescens* biotyping system, 2-3
- Thiophene carboxylic acid hydrazide (TCH), against unusual mycobacteria, 322-323
- Throat, *Serratia marcescens* in, 5
- Ticarcillin
 against *Acinetobacter calcoaceticus*, 199
 against *Bacteroides fragilis*, 202
 against *Citrobacter freundii*, 196
 against coagulase-negative streptococci, 193
 against *Enterobacter aerogenes*, 196
 against *Enterobacter cloacae*, 196
 against *Enterococcus* spp., 194
 against *Escherichia coli*, 197
 against *Haemophilus influenzae*, 201
 against *Haemophilus parainfluenzae*, 201
 against *Klebsiella oxytoca*, 197
 against *Klebsiella pneumoniae*, 197
 against *Moraxella catarrhalis*, 201
 against *Morganella morganii*, 197
 against *Neisseria gonorrhoeae*, 202
 against *Neisseria* spp., 202
 against *Prevotella bivia-disiens*, 202
 against *Proteus mirabilis*, 197
 against *Proteus vulgaris*, 198
 against *Providencia rettgeri*, 198
 against *Providencia stuartii*, 198
 against *Pseudomonas aeruginosa*, 199
 against *Salmonella* spp., 198
 against *Serratia marcescens*, 199
 against *Shigella* spp., 199
 against *Staphylococcus aureus*, 192-193
 against *Streptococcus agalactiae*, 193
 against *Streptococcus pneumoniae*, 194
 against *Streptococcus pyogenes*, 193
 against *Streptococcus*, viridans group, 194
 in teicoplanin fluorescence polarization immunoassay, 21
- Ticarcillin-clavulanic acid, against Gram-negative bacilli, 248
- TMP/SMZ. See Trimethoprim-sulfamethoxazole
- Tobramycin
 against *Klebsiella pneumoniae*, 25-29
 qualitative susceptibility tests and, 234-235
 quantitative MIC tests and, 234-235
 in teicoplanin fluorescence polarization immunoassay, 21
- Topical agents, against *Staphylococcus aureus*, 9-16
- Torulopsis glabrata*
 BacT/Alert blood culture system in assessment of, 33
- in invasive candidiasis, 57
- Tracheal aspirates, *Serratia marcescens* in, 1-7
- Trehalose dimycolate, *Nocardia asteroides*, 291-301
- Treponema pallidum*, cross-reactive antibodies between *Borrelia burgdorferi* and, 43-51
- Treponema phagedenis*, cross-reactive antibodies between *Borrelia burgdorferi* and, 43-51
- Trichomonas vaginalis*, rifaximin against, 111-118
- Trichomoniasis, Centers for Disease Control 1991 estimates of, 174
- Trichuris trichiura*
 conventional microscopic examination for, 339
 ELISA for, 339
- Triglycerides, abnormal levels of, in teicoplanin recovery, 17-24
- Trigonelline, in *Serratia marcescens* biotyping system, 2-3
- Trimethoprim, in teicoplanin fluorescence polarization immunoassay, 21
- Trimethoprim-sulfamethoxazole (TMP/SMZ)
 against Gram-negative bacilli, 248
 against *Haemophilus influenzae*, 249
 against *Klebsiella pneumoniae*, 25-29
 against *Staphylococcus aureus*, 13
 against *Staphylococcus* spp., 248
- Tube culture, for detection of respiratory syncytial virus, 105-109, 325-329
- Tuberculosis, disseminated, unusual presentation of, 67-71
- Tuberculous fascitis, miliary tuberculosis originally presenting as, 67-71
- Turnaround times, problem of, 237-238
- Tylosin, against staphylococci, 210
- Ureaplasma urealyticum*
 ciprofloxacin against, 114
 doxycycline against, 114
 erythromycin against, 114
 rifaximin against, 111-118
- Urethritis, Centers for Disease Control 1991 estimates of, 174
- Urinary tract infections
 catalase activity in, 93-97
Klebsiella pneumoniae in, 25-29
- Urine specimens
 leaky, 141-143
Serratia marcescens in, 1-7
 sexually transmitted diseases in men detected in, 180-182
- Vaginitis, direct detection of, 181-183
- Vancomycin
 against coagulase-negative staphylococci, 224-225
 against *Enterococcus* group D, 89-91
 against *Enterococcus* spp., 248
- against *Gemella morbillorum*, 131-132
 against miliary tuberculosis, 67
 against staphylococci, 205-213, 248
 against *Staphylococcus aureus*, 12, 224-225
 against *Streptococcus* spp., 248
 teicoplanin relationship to, 17-24
- Veillonella* sp., BacT/Alert blood culture system in assessment of, 33
- Vero cell subline C1008, in rapid detection of herpes simplex virus, 61-66
- Virapap DNA hybridization assay, for human papillomavirus, 173-184
- Virginiamycin, against staphylococci, 205-213
- Virus culture, for respiratory syncytial virus, 325-329
- Vitek Gram-Positive Susceptibility card, in assessment of aminoglycoside resistance, 145-148
- Vitek system, for enterococcal species identification and detection of high-level aminoglycoside resistance, 119-122
- Vitek System GPI card, in staphylococcal speciation, 205-213
- Vitek Urine Identification-3 panel, for bacteriuria, 93-97
- Vomiting, in clarithromycin therapy, 215-221
- WBCs. See White blood cells
- Western blot analysis
 of HIV-1, 331-335
 in murine model for recognition of nocardial infections, 291-301
- White blood cells (WBCs), in *Clostridium difficile* toxin assay, 313-315
- Whole virus lysate-based enzyme immunoassay, for HIV-1 antibodies, 331-335
- WIN57273
 against enterococci, 83-85
 against *Mycobacterium avium-intracellulare*, 351
 against *Mycobacterium chelonae-fortuitum*, 351
 against *Staphylococcus aureus*, 9-16
- Wounds, *Serratia marcescens* in, 1-7
- Xanthomonas maltophilia*, rifaximin against, 113
- Yeast
 BacT/Alert blood culture system in assessment of, 33
 rifaximin against, 111-118
- Yersinia enterocolitica*
 ciprofloxacin against, 137
 rifaximin against, 113
- Yersinia pseudotuberculosis*
 ciprofloxacin against, 277-289
 enoxacin against, 277-289
 lomefloxacin against, 277-289
 quinolones against, 277-289

